stockrowPuma Biotechnology, Inc.
PBYI Healthcare Biotechnology
Puma Biotechnology, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $228.4 million, down 0.91% from fiscal 2024.
- Revenue
- +7.75%
- EPS
- +33.3%
- Free cash flow
- −88.5%
- Total debt
- −79.8%
Quarter to June 2026, against a year earlier
Follow PBYI
Alert me
Puma Biotechnology, Inc. (PBYI) EV/Sales
As of 6 November 2026, Puma Biotechnology, Inc. (PBYI) trades at a EV/Sales of 1.5×. Over the past ten years it has ranged from 0.0× (June 2018) to 15.5× (July 2018); the current reading is higher than 81% of that period. That is below the Biotechnology industry median of 9.0× and below the Healthcare sector median of 3.6×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 1.0× | 103.95% |
| FY2024 | 0.5× | (46.12%) |
| FY2023 | 0.9× | 2.10% |
| FY2022 | 0.9× | 71.52% |
| FY2021 | 0.5× | (70.53%) |
| FY2020 | 1.8× | 53.75% |
| FY2019 | 1.2× | (61.56%) |
| FY2018 | 3.0× | — |
| FY2017 | 0.0× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2026 | 1.5× | 37.77% |
| Mar 2026 | 1.1× | 5.77% |
| Dec 2025 | 1.0× | (0.31%) |
| Sep 2025 | 1.0× | 106.36% |
| 32 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| NGNE Neurogene Inc. compare | n/m |
| FTH Faeth Therapeutics, Inc. compare | n/m |
| SLBT SL SCIENCE HLDG compare | n/m |
| CLYM Climb Bio, Inc. compare | n/m |
| PBYI Puma Biotechnology, Inc. | 1.5× |
| CAPR Capricor Therapeutics, Inc. compare | 13.5× |
| OVID Ovid Therapeutics compare | 58.7× |
| ENTX Entera Bio Ltd. compare | 643× |
| YDES YD Bio Limited compare | — |
| Biotechnology industry median | 9.0× |
| Healthcare sector median | 3.6× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)